Cancer of unknown primary site: a review of 28 cases and the efficacy of cisplatin/docetaxel therapy at a single institute in Japan.
We evaluated the efficacy and toxicity of cisplatin/docetaxel (CDDP/TXT) chemotherapy and identified prognostic factors in Japanese patients with cancer of unknown primary site (CUP). Twenty-eight consecutive patients seen at a single institute were reviewed retrospectively. Sixteen patients were treated with TXT 80 mg/m2, followed by CDDP 75 mg/m2. The overall response rate to CDDP/TXT treatment was 62.5%, with a median survival time (MST) of 22.7 months. Common adverse reactions were myelosuppression and hyponatremia. The MST of all 28 patients with CUP was 8.3 months, and the 1-year overall survival rate was 45.6%. Univariate analysis identified 5 prognostic factors:performance status, liver involvement, bone involvement, pleural involvement, and lymph node involvement. In conclusion, CDDP/TXT chemotherapy is effective with tolerable toxicity in patients with CUP. Japanese patients with CUP might be chemosensitive and may survive longer.
Nishimori
Hisakazu
H
Division of Medical Oncology and Hematology, Cancer Institute Hospital, Koto-ku, Tokyo 135-8550, Japan. n-mori@md.okayama-u.ac.jp
Takahashi
Shunji
S
Kiura
Katsuyuki
K
Ennishi
Daisuke
D
Kobayashi
Takayuki
T
Sano
Koji
K
Shinozaki
Eiji
E
Yokoyama
Masahiro
M
Mishima
Yuko
Y
Terui
Yasuhito
Y
Chin
Keisho
K
Mizunuma
Nobuyuki
N
Ito
Yoshinori
Y
Nishimura
Seiichiro
S
Takeuchi
Kengo
K
Ishikawa
Yuichi
Y
Oguchi
Masahiko
M
Tanimoto
Mitsune
M
Hatake
Kiyohiko
K
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D000077143:Docetaxel; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007010:Hyponatremia / Q000139:chemically induced; D007564:Japan; D008297:Male; D008875:Middle Aged; D009382:Neoplasms, Unknown Primary / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin